Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1. (Currently Amended) A single-chain multi-functional polypeptide comprising
- (a) a first domain comprising a binding-site of an antibody or an immunoglobulin chain thereof specifically recognizing the CD19 antigen; and
- (b) a second domain comprising a binding site of an antibody or an immunoglobulin chain thereof recognizing the human CD3 antigen,

wherein said domains are arranged in the order V_LCD19- V_HCD19-V_HCD3-V_LCD3.

- 2. (Original) The polypeptide of claim 1, wherein said two domains are connected by a polypeptide linker.
- 3. (Previously Presented) The polypeptide of claim 1, wherein said first and/or second domain correspond to a V_H and V_L region from a natural antibody.
- 4. (Previously Presented) The polypeptide of claim 1, wherein said antibody is monoclonal antibody, synthetic antibody, or humanized antibody.
- 5. (Previously Presented) The polypeptide of claim 4, wherein at least one of said domains is a single-chain fragment of the variable region of the antibody.
 - 6. (Canceled)
- 7. (Previously Presented) The polypeptide of claim 2, wherein said polypeptide linker comprises a plurality of glycine, alanine, serine residues or combinations thereof.
- 8. (Previously Presented) The polypeptide of claim 2, wherein said polypeptide linker comprises a plurality of consecutive copies of an amino acid sequence.

- 9. (Previously Presented) The polypeptide of claim 2, wherein said polypeptide linker comprises 1 to 5 amino acid residues.
- 10. (Previously Presented) The polypeptide of claim 9, wherein said polypeptide linker comprises the amino acid sequence Gly Gly Gly Ser.
- 11. (Previously Presented) The polypeptide of claim 1, comprising at least one of said first or second domains, wherein said first domain comprises at least one CDR of the V_H and V_L region comprising the amino acid sequence encoded by the DNA sequence depicted in Figure 8 from nucleotides 82 to 414 (V_L) and nucleotides 460 to 831 (V_H) and, wherein said second domain comprises at least one CDR of the V_H and V_L region comprising the amino acid sequence encoded by the DNA sequence depicted in Figure 8 from nucleotides 847 to 1203 (V_H) and nucleotides 1258 to 1575 (V_L).
 - 12. (Previously Presented) The polypeptide of claim 1, wherein
 - (a) said binding site of the first domain has an affinity of at least about 10⁻⁷ M; and/or
 - (b) said binding site of the second domain has an affinity of less than about 10^{-7} M.
- 13. (Previously Presented) The polypeptide of claim 1, wherein said polypeptide is a bispecific single-chain antibody.
- 14. (Previously Presented) The polypeptide of claim 1, comprising at least one further domain.
- 15. (Original) The polypeptide of claim 14, wherein said further domain is linked by covalent or non-covalent bonds.
- 16. (Previously Presented) The polypeptide of claim 14, wherein said at least one further domain comprises an effector molecule having a conformation suitable for biological activity, capable of sequestering an ion or selective binding to a solid support or to a preselected determinant.

17.-19. (Canceled)

20. (Previously Presented) A method for the preparation of a single-chain multifunctional polypeptide comprising:

cultivating a cell transfected with a polynucleotide which upon expression encodes the single-chain multi-functional polypeptide of claim 1; and

isolating said polypeptide from the cell.

- 21. (Currently Amended) A composition comprising a single-chain multifunctional polypeptide comprising:
 - (a) a first domain comprising a binding-site of an antibody or an immunoglobulin chain thereof specifically recognizing the CD 19 antigen; and
 - (b) a second domain comprising a binding site of an antibody or an immunoglobulin chain thereof recognizing the human CD3 antigen, wherein said domains are arranged in the order V_LCD19- V_HCD19-V_HCD3-V_LCD3.
- 22. (Previously Presented) The composition of claim 21 which is a pharmaceutical composition optionally further comprising a pharmaceutically acceptable carrier.
- 23. (Original) The composition of claim 21, which is a diagnostic composition optionally further comprising suitable means for detections.

24-29. (Canceled)

- 30. (Currently Amended) A method for the treatment of B-cell malignancies, B-cell mediated autoimmune diseases or the depletion of B-cells comprising administering to a human afflicted with said malignancies, diseases or depletion, an effective amount of:

 a single-chain multi-functional polypeptide comprising:
 - (a) a first domain comprising a binding-site of an antibody or an immunoglobulin chain thereof specifically recognizing the CD 19 antigen; and

- (b) a second domain comprising a binding site of an antibody or an immunoglobulin chain thereof recognizing the human CD3 antigen, wherein said domains are arranged in the order V_LCD19 - V_HCD19 - V_HCD3 - V_LCD3 .
- 31.-32. (Canceled)
- 33. (Previously Presented) The method of claim 30, wherein said B-cell malignancy is non-Hodgkin lymphoma.
 - 34.-36. (Canceled)
- 37. (Previously Presented) The method of claim 20, wherein said first and/or second domain correspond to a V_H and V_L region from a natural antibody.
 - 38.-39. (Canceled)
- 40. (Previously Presented) The method of claim 20, wherein the single-chain multi-functional polypeptide comprises at least one further domain.
- 41. (Previously Presented) The method of claim 30, wherein said first and/or second domain correspond to a V_H and V_L region from a natural antibody.
 - 42.-43. (Canceled)
- 44. (Previously Presented) The polypeptide of claim 1, comprising at least one of said first or second domains, wherein said first domain comprises at least two CDRs of the V_H and V_L region comprising the amino acid sequence encoded by the DNA sequence depicted in Figure 8 from nucleotides 82 to 414 (V_L) and nucleotides 460 to 831 (V_H) and, wherein said second domain comprises at least two CDRs of the V_H and V_L region comprising the amino acid sequence encoded by the DNA sequence depicted in Figure 8 from nucleotides 847 to 1203 (V_H) and nucleotides 1258 to 1575 (V_L).
- 45. (Previously Presented) The polypeptide of claim 1, comprising at least one of said first or second domains, wherein said first domain comprises the three CDRs of the V_H and V_L region comprising the amino acid sequence encoded by the DNA sequence depicted in Figure 8 from nucleotides 82 to 414 (V_L) and nucleotides 460 to 831 (V_H) and,

Atty. Dkt. No. 028622-0102 Appln. No. 09/673,735

wherein said second domain comprises the three CDRs of the V_H and V_L region comprising the amino acid sequence encoded by the DNA sequence depicted in Figure 8 from nucleotides 847 to 1203 (V_H) and nucleotides 1258 to 1575 (V_L).